Myocarditis is recognized as a rare but serious adverse reaction to messenger RNA (mRNA) vaccination against COVID-19.

Myocarditis and pericarditis are types of heart inflammation. Myocarditis affects the middle layer of heart muscle, and pericarditis only affects the heart’s outer lining. Myocarditis and pericarditis ...

Stanford researchers identify a two-step immune reaction underlying rare myocarditis cases after mRNA COVID vaccination, primarily in adolescent males and young men. Cases typically resolve quickly ...

People with postvaccine myocarditis did not share the typical mid-term complications associated with conventional myocarditis, based on a population-based study from France. With 18-month follow-up of ...

Patients who develop myocarditis within the first month of receiving immune checkpoint inhibitor therapy are more likely to have MC fatality.

A new expert consensus decision pathway from the American College of Cardiology (ACC) provides guidance around the management of myocarditis from diagnosis to follow-up. In light of recent advances in ...

The updated 2024-2025 mRNA COVID vaccine from Moderna does not appear to carry the same risk for myocarditis in young adults that the first mRNA COVID vaccines did, suggested research presented at the ...

The diagnostic criteria for myocarditis and degree of certainty of diagnosis were adapted from the case definition and classification of the Brighton Collaboration (Pandemic Emergency Response Process ...

Patients who developed myocarditis within the first month of receiving immune checkpoint inhibitor therapy were more likely ...

Clinical impact of single nucleotide polymorphisms (SNPs) in PDCD1 in patients with non-small cell lung cancer (NSCLC) receiving anti-PD1 immunotherapy. This is an ASCO Meeting Abstract from the 2025 ...

Early myocarditis onset may predict treatment-related fatality in patients receiving immune checkpoint inhibitor therapy.